NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Women's Hair Loss

LITHIA SPRINGS, Ga., April 23 /PRNewswire/ -- NIOXIN(R) Research Laboratories, the leader in professional skincare for the scalp, has entered into an agreement with HairDX, LLC to market the world's first genetic test for predicting female hair loss. NIOXIN(R), known throughout the industry as a force in the thinning hair category, will market this test to consumers through multiple vehicles including professional salons and beauty stores.

Today's launch offers a chance at prevention for women at risk of losing their hair. The easy to understand test provides an accurate and understandable genetic analysis of a woman's likelihood of developing a common type of hair loss called Female Androgenetic Alopecia.

Scientists have identified markers associated with female hair loss and the test uses these markers to provide women with insight into their potential for hair loss. By providing a score called the CAG repeat score, a woman can learn about her likelihood of hair loss. A smaller CAG repeat score is associated with a higher risk for significant hair loss, also known as Ludwig grade II or III hair loss, while a larger repeat score is associated with a lower risk for hair loss.

"Scientists discovered that the percentage of the female population with a CAG repeat length of 15 or less, NOT suffering from a Ludwig grade II or III hair loss was only 2.3%," says Dr. Nathan Vandergraft, a Statistician and Research Scientist at the University of California, Irvine.

"NIOXIN is pleased to join forces with HairDX to be the first to bring this innovative technology to market for the benefit of women around the world who experience hair loss and seek a greater understanding of this issue. This is a highly sensitive concern for women and we take great pride in empowering them with valuable information in a format that ensures confidentiality," says Brian Graham, CEO of NIOXIN(R) Research Laboratories.

This simple and easy to use test costs $149. The customer orders the test kit on the Internet, at www.nioxin.com, and it is shipped to her home. After swabbing the inner cheek for several seconds the customer returns the swab to the HairDX lab. HairDX performs a confidential and anonymous genetic analysis of her CAG repeat score. The results are delivered via a secure and private Web site.

"This test is revolutionary. The cause of female hair loss is often elusive and at times misdiagnosed," said HairDX CEO Andy Goren. "While the cause of female hair loss may not be completely understood genetically, there are strong genetic markers that are associated with the risk of developing Androgenetic Alopecia. HairDX developed a breakthrough patent pending test for those markers."

NIOXIN(R) Research Laboratories has, for 20 years provided consumers and professionals with products that help restore scalp and hair health. The introduction of the Female Hair Loss Test allows the Company to help consumers realize the importance of scalp health in relation to healthy hair. This is very beneficial information for women when considering any kind of preventative treatment.

About NIOXIN(R) Research Laboratories Inc.

NIOXIN(R) is the leading provider of advanced skincare solutions that treat the scalp to improve the appearance of fine and thinning hair. Founded in 1987 by Eva Graham, this privately-held company has been dedicated to providing education and products for consumers through the professional salon industry around the world. Distributed in more than 42 countries on six continents, NIOXIN(R) continues to define the meaning of innovation and leadership for the global market of fine and thinning hair.

Additional information is available at www.nioxin.com or at 800-789-9617.

About HairDX

HairDX was founded by leading researchers and specialists in genetic analysis and hair therapies. The company is dedicated to helping people make the right decisions about hair care, treatment and restoration by providing accurate and accessible personalized scientific information.

Among HairDX founders is William V. Murray former Division President of the Molecular Biology Division of Applied BioSystems, Inc., who formerly served in various executive leadership positions within Medtronic, Andy Goren, former CEO of MobileWise, Inc. and GeePS, Inc., Eran Goren, CEO of enCircle Media, Inc., Professor Doron Lancet, PhD, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Dr Elon Pras, Director of the Institute of Human Genetics, Sheba Medical Center in Tel-Hashomer, Israel, Sharon Keene, MD and President and Medical Director of Physician's Hair Institute, in Tucson, Arizona and nationally recognized for her pioneering work in the hair transplant field, Dr. Peter Novak, a Neurologist at the University of Massachusetts Medical Center, Elliott J. Stein, an intellectual property attorney and co-founder of GeePS, Inc., Mace Wolf, and Darlene Frie. HairDX, LLC is a subsidiary of myGenopedia, Inc.

More information is available at www.hairdx.com and www.hairdx.com/spanish

SOURCE NIOXIN(R) Research Laboratories Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.